Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96CW6
UPID:
S7A6O_HUMAN
Alternative names:
ADAMS proteinase-related protein; Solute carrier family 7 member 6 opposite strand transcript
Alternative UPACC:
Q96CW6; Q8TCZ3; Q9H8R8
Background:
The Probable RNA polymerase II nuclear localization protein SLC7A6OS, also known as ADAMS proteinase-related protein and Solute carrier family 7 member 6 opposite strand transcript, plays a pivotal role in directing RNA polymerase II nuclear import. This process is crucial for the transcription of DNA into RNA, a fundamental step in gene expression and cellular function.
Therapeutic significance:
SLC7A6OS is linked to Epilepsy, progressive myoclonic 12 (EPM12), a disorder characterized by seizures, neurodegeneration, and neurocognitive impairment. Understanding the role of SLC7A6OS could open doors to potential therapeutic strategies for this debilitating condition.